Heparin MOA – Orris AI

Heparin MOA

Reading File

Finding Sources

Reading File

I now have comprehensive information from both Harrison's and Katzung's. Here is a complete summary:

Heparin — Mechanism of Action

Structure

Heparin is a sulfated polysaccharide (glycosaminoglycan) isolated from mammalian tissues rich in mast cells (most commercial preparations from porcine intestinal mucosa). It is a heterogeneous mixture with a molecular weight range of 5,000–30,000 Da, composed of repeating disaccharide units of D-glucuronic acid and N-acetyl-D-glucosamine.

Core MOA: Antithrombin Activation

Heparin acts as an anticoagulant cofactor — it does not directly inhibit clotting factors itself. Instead:

Binds antithrombin (AT) via a unique pentasaccharide sequence found on ~one-third of commercial heparin chains. Chains lacking this pentasaccharide have little or no anticoagulant activity.
Induces conformational change in antithrombin's reactive center loop, making its active site more accessible to target proteases.
Accelerates AT inhibition of clotting factors by ≥1000-fold, primarily:
- Thrombin (Factor IIa)
- Factor Xa
- Also Factor IXa, XIa, XIIa (to lesser degrees)
Acts as a catalytic cofactor: once the AT-protease complex forms, heparin is released intact and can bind more antithrombin molecules (not consumed in the reaction).

Differential Inhibition: Xa vs. Thrombin

Target	Requirement
Factor Xa inhibition	Pentasaccharide binding to AT alone is sufficient
Thrombin (IIa) inhibition	Heparin must simultaneously bind both AT and thrombin (acts as a template) — requires chains of ≥18 saccharide units

This distinction explains why LMW heparins (shorter chains) inhibit Xa >> thrombin, while unfractionated heparin (UFH) inhibits both.

Antithrombin's Role

Antithrombin is a serine protease inhibitor (serpin) synthesized in the liver, circulating at ~2.6 μM. It acts as a suicide substrate — it irreversibly traps its target proteases. Heparin dramatically accelerates this normally slow reaction.

Limitations of UFH (and their mechanisms)

Limitation	Mechanism
Poor bioavailability at low doses	Binds endothelial cells and macrophages
Dose-dependent clearance	Macrophage binding
Variable anticoagulant response	Binds plasma proteins (variable levels between patients)
Reduced activity near platelet-rich thrombi	Neutralized by platelet factor 4 (PF4) from activated platelets
Limited activity against clot-bound thrombin / prothrombinase-bound Xa	Reduced capacity of heparin-AT complex to reach these targets

Reversal

Protamine sulfate (basic polypeptide from salmon sperm) binds heparin with high affinity → protamine-heparin complexes are cleared. 1 mg protamine neutralizes ~100 units of heparin.

Monitoring

UFH: aPTT (target therapeutic range), or anti-Xa levels (0.3–0.7 units/mL)
LMWHs: generally do not require routine monitoring (predictable pharmacokinetics); anti-Xa used in special circumstances

— Harrison's Principles of Internal Medicine 22E, p. 991 | Katzung's Basic and Clinical Pharmacology 16th Ed, p. 959

Heparin during dialysis

Finding Sources

Reading File

Excellent — rich content from both sources. Here's a comprehensive answer:

Heparin During Dialysis

Why Anticoagulation Is Needed

Contact of blood with the "foreign" surfaces of the dialyzer membrane triggers the coagulation cascade. Without anticoagulation, clotting within the dialyzer hollow fibers causes:

Loss of dialyzer surface area → reduced solute clearance
Potential loss of significant patient blood volume in the clotted circuit

Anticoagulation must be effective before blood-membrane contact — clots that form at the start cannot be reversed.

Standard UFH Protocol

Parameter	Detail
Drug	Unfractionated heparin (UFH) — most commonly used
Initial bolus	~50 units/kg (weight-based) or fixed 1,000–5,000 U immediately after needle insertion and access patency confirmed
Timing of bolus	Allow ~3 minutes before blood reaches the extracorporeal circuit (so heparin achieves systemic circulation first)
Maintenance	Continuous infusion 1,000–1,500 U/hr, OR intermittent boluses (500–2,000 U) as needed
Stop time	Infusion stopped 15–60 minutes before end of dialysis to allow heparin levels to fall before needle removal

The continuous infusion method is preferred over intermittent boluses because boluses cause episodic over- and under-anticoagulation and increase nursing time.

During a session, heparin concentration declines due to both metabolism and adsorption onto the extracorporeal surface, hence continuous infusion is needed to maintain anticoagulation.

LMWH as Alternative

Given as a single bolus at the start of dialysis
Predictable pharmacokinetics; no routine monitoring needed
May not maintain anticoagulation for extended sessions (e.g., nocturnal HD)

Patients at High Risk of Bleeding

Anticoagulation Strategy	Clinical Condition
No anticoagulation or regional anticoagulation	Active bleeding, significant bleeding risk, major thrombostatic defect, major surgery within 7 days, intracranial surgery within 14 days, visceral organ biopsy within 72 hrs, pericarditis
Low-dose heparin (500–1,000 U bolus + 500–750 U/hr)	Major surgery >7 days prior, visceral biopsy >72 hrs, minor surgery 8 hrs prior
Low-dose heparin or no anticoagulation	Minor surgery within 72 hrs, major surgery 8 hrs prior

Anticoagulation-Free Dialysis (When Heparin Is Contraindicated)

Strategies to prevent clotting without heparin:

Pre-rinse circuit with heparinized saline (primes tubing, then flushed out)
Use a less thrombogenic dialyzer
Flush circuit with 100–200 mL normal saline every 15–30 minutes
Maintain high blood flow rates to reduce stasis

Regional Anticoagulation Alternatives

Regional citrate anticoagulation (common in acute/ICU dialysis):

Citrate infused into the arterial (pre-dialyzer) line → chelates ionized calcium → inhibits coagulation locally in the circuit
Calcium infused into the venous (post-dialyzer) line → restores systemic coagulability
Dialysate is calcium-free
Advantage: anticoagulation confined to the circuit, minimal systemic effect

Regional heparin–protamine:

Heparin infused pre-dialyzer, protamine infused post-dialyzer to neutralize it
Labor-intensive and prone to error; less commonly used

HIT Consideration

Patients with known or suspected heparin-induced thrombocytopenia (HIT) must not receive UFH or LMWH. Alternative anticoagulants (e.g., argatroban, bivalirudin) are used in this setting.

— NKF Primer on Kidney Diseases 8e, p. 601 | Brenner & Rector's The Kidney, p. 2732

What happens if heparin dose missed ?

Finding Sources

Reading File

Excellent — very detailed content directly addressing this. Here's the answer:

What Happens if Heparin Dose is Missed During Dialysis?

The Core Problem: Extracorporeal Circuit Clotting

When heparin is absent or inadequate during hemodialysis, the coagulation cascade is activated by blood contact with foreign surfaces of the dialyzer membrane. This leads to clotting of the extracorporeal circuit — the most direct and immediate consequence.

Sequence of Events

Blood contacts the dialyzer membrane without adequate anticoagulation → coagulation cascade is triggered immediately
Local clotting inside the hollow fibers begins — this is irreversible once established
Progressive loss of dialyzer surface area → reduced clearance of uremic toxins and solutes
If severe: the entire dialyzer can clot → loss of an appreciable volume of patient blood trapped in the clotted circuit (a meaningful blood loss for already-anemic dialysis patients)
Reduced dialysis adequacy (lower Kt/V) for that session

Specific Causes of "Missed" Heparin

Comprehensive Clinical Nephrology specifically identifies these as correctible causes of circuit clotting due to inadequate heparin:

Error	Consequence
Incorrect heparin loading dose	Subtherapeutic from the start
Insufficient time after loading dose (< 3 min before blood pump started)	Blood reaches membrane before systemic anticoagulation achieved → local fiber clotting
Incorrect pump setting for continuous infusion	Underanticoagulation develops mid-session
Delayed start of the heparin pump	Gap in anticoagulation coverage
Failure to release the heparin line clamp	No heparin delivered despite pump running
Poor priming technique (air retention in dialyzer)	Promotes clot formation

Why Heparin Can Become Inadequate Mid-Session (Even If Given)

Even with a correct initial bolus, heparin concentration steadily declines during dialysis through:

Metabolism (hepatic/endothelial)
Adsorption onto the extracorporeal surface

This is why a continuous infusion (~1,000 U/hr) is recommended throughout the session — a single bolus alone is often insufficient, especially for longer sessions (e.g., nocturnal HD).

Management When Clotting Is Detected

Prompt recognition of the underlying cause
Identify and correct the specific error (clamp, pump setting, dose)
Ongoing heparin dose adjustment for the current and future sessions
If vascular access-related poor flow is contributing → vascular access revision
If the dialyzer is already clotted — the session must be terminated and the clotted circuit discarded

Context: Intentional Heparin-Free Dialysis

When heparin is deliberately withheld (active bleeding, post-surgery, pericarditis), strategies to minimize clotting include frequent saline flushes (100–200 mL every 15–30 min), pre-rinsing with heparinized saline, using less thrombogenic dialyzers, or regional citrate anticoagulation.

— Comprehensive Clinical Nephrology 7th Ed, p. 1308 | NKF Primer on Kidney Diseases 8e, p. 601

This is a shared conversation. Sign in to Orris to start your own chat.